Aptose Biosciences
Dr. Killion has been named to the newly established position of Vice President of Chemistry, Manufacture, and Control (CMC) after having joined Aptose in 2020 as Senior Director, CMC. In this role, he assumes oversight of manufacturing, quality control, and formulation development for CG-806 and APTO-253. Dr. Killion’s more than 20 years of CMC experience span roles in Relypsa, Gilead, Genentech, Roche, and Syntex, and include responsibilities in developing, validating, and implementing quality control processes for clinical stage and commercial programs, oversight of stability management for commercial drug products and pharmaceutical ingredients, as well as responsibility for solid and liquid oral dosage formulation development.
This person is not in any offices
Aptose Biosciences
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address the unmet clinical needs in multiple hematologic malignancies.